

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:29:39 ON 05 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:29:56 ON 05 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUL 2007 HIGHEST RN 941231-35-2

DICTIONARY FILE UPDATES: 4 JUL 2007 HIGHEST RN 941231-35-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10566403.str



chain nodes :
 11 12 13 14 15 16 17
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 4-11 7-16 11-12 12-13 12-14 12-15 16-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 4-11 5-7 7-8 7-16 11-12 12-13 12-14 12-15 16-17
 exact bonds :
 6-9 8-9
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:N,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 N,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:30:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 132 TO ITERATE

100.0% PROCESSED 132 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1951 TO 3329

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:30:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2529 TO ITERATE

100.0% PROCESSED 2529 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

L3 9 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 11:30:26 ON 05 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jul 2007 VOL 147 ISS 2

FILE LAST UPDATED: 4 Jul 2007 (20070704/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:410811 CAPLUS

DOCUMENT NUMBER: 146:421837

TITLE: Preparation of fused pyrrole derivatives as GR modulators

INVENTOR(S): Sone, Toshihiko; Sawaki, Rieko; Nakajima, Tomoko

PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan

SOURCE: PCT Int. Appl., 403pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007040166	A1	20070412	WO 2006-JP319426	20060929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			



PRIORITY APPLN. INFO.:

JP 2005-286576

A 20050930

OTHER SOURCE(S): MARPAT 146:421837

GI



AB Title compds. I [R1 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R2 = H, halo, carboxyl, etc.; -W4:W5-W6:W7- = -CR4:CR5-CR6:CR7-, -N:CR5-CR6:CR7-, -CR4:N-CR6:CR7-, etc.; R4-R7 = -E-A; E = single bond, -O-, -CO-, etc.; when E is a single bond, A is H, halo, cyano, etc.; when E is -O-, -CO-, etc., A is H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R8 = -OR11, -SR11, -N(R11)R12; R11, R12 = H, (un)substituted alkyl; R9 = alkyl substituted with halo, cycloalkyl substituted with halo; R10 = -[C(R13)R14]n-R15; R13, R14 = H, alkyl, halo; R13 and R14 may combine to form a oxo group; or R13 and R14, together with the carbon atom to which they are attached; form a cycloalkane (one or two -CH2- in cycloalkane may be replaced with -NH-, -S-, -S(:O)-, etc.); n = 0-10; R15 = hydroxy, (un)substituted alkyl, (un)substituted alkenyl, etc.], prodrugs or pharmaceutically acceptable salts were prepared For example, reaction of 1-(1-benzyl-6-nitro-1H-indol-3-yl)-2,2,2-trifluoroethanone, e.g., prepared from 6-nitroindole in 2 steps, with trimethylphosphonium iodide followed by treatment with piperidine afforded compound II. In glucocorticoid receptor (GR) binding assays, compound II exhibited the inhibitory activity of 92% at 100 nM. Compds. I are claimed useful for the treatment of inflammation and diabetes.


IT 934224-34-7P.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyrrole derivs. as GR modulators for treatment of inflammation and diabetes)

RN 934224-34-7 CAPLUS

CN 1H-Indole-3-acetic acid, α -hydroxy-7-[[[4-methylphenyl)sulfonyl]amino]-1-(phenylmethyl)- α -(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:136598 CAPLUS

DOCUMENT NUMBER: 142:240323

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT₆ receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zuera, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich

PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain

SOURCE: PCT Int. Appl., 427 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014045	A1	20050217	WO 2004-EP8514	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2228268	A1	20050401	ES 2003-1815	20030730
ES 2228268	B1	20060701		
AU 2004262488	A1	20050217	AU 2004-262488	20040729
CA 2534099	A1	20050217	CA 2004-2534099	20040729
EP 1660131	A1	20060531	EP 2004-741321	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007009597	A1	20070111	US 2006-566402	20060705
PRIORITY APPLN. INFO.:			ES 2003-1815	A 20030730
			WO 2004-EP8514	W 20040729

OTHER SOURCE(S):
GI

CASREACT 142:240323; MARPAT 142:240323

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.;

A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2Ph; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).


IT 844486-21-1P 844486-22-2P 844486-23-3P
844486-24-4P 844486-25-5P 844486-26-6P
844486-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and sulfonamides as components of active combination with NPY receptor affinity and 5-HT6 receptor affinity)


RN 844486-21-1 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-22-2 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 844486-23-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-24-4 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-25-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-26-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME).



RN 844486-27-7 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4. ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:136568 CAPLUS

DOCUMENT NUMBER: 142:240322

TITLE: Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity

INVENTOR(S): Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zuera, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constanca,

PATENT ASSIGNEE(S): Jordi; Buschmann, Helmut-Heinrich
 SOURCE: Laboratorios del Esteve S. A., Spain
 PCT Int. Appl., 451 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014000	A1	20050217	WO 2004-EP8515	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2228267	A1	20050401	ES 2003-1814	20030730
ES 2228267	B1	20060701		
AU 2004262489	A1	20050217	AU 2004-262489	20040729
CA 2534100	A1	20050217	CA 2004-2534100	20040729
EP 1648468	A1	20060426	EP 2004-763612	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007059364	A1	20070315	US 2006-566100	20061026
PRIORITY APPLN. INFO.:			ES 2003-1814	A 20030730
			WO 2004-EP8515	W 20040729
OTHER SOURCE(S):			MARPAT 142:240322	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated (hetero)cycloalkyl; R6-R9 = H, alkyl, (un)saturated (hetero)cycloalkyl, etc.; A = CHR18, CHR18CH2; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. Thus, reacting 6-chloro-1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride with 2-(2-chloroacetamide)-2',5-dichlorobenzophenone in the presence of K2CO3 in DMF followed by treating of the free base with HCl/EtOH afforded 61% III.HCl. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).


IT 844486-21-1P 844486-22-2P 844486-23-3P
 844486-24-4P 844486-25-5P 844486-26-6P
 844486-27-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of amides and sulfonamides as components of active combination
with NPY receptor affinity and 5-HT₆ receptor affinity)


RN 844486-21-1 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]-
(9CI) (CA INDEX NAME)




RN 844486-22-2 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-
indol-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 844486-23-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-
yl]- (9CI) (CA INDEX NAME)




RN 844486-24-4 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-
(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-25-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-26-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)



RN 844486-27-7 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:136551 CAPLUS
 DOCUMENT NUMBER: 142:219149
 TITLE: Preparation of indol-7-sulfonamide derivatives and their use as 5-HT6 modulators
 INVENTOR(S): Merce Vidal, Ramon; Codony Soler, Xavier; Dordal Zuera, Alberto
 PATENT ASSIGNEE(S): Laboratorios del Esteve S. A., Spain
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013979	A1	20050217	WO 2004-EP8513	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2222830	A1	20050201	ES 2003-1808	20030730
ES 2222830	B1	20060216		
AU 2004262487	A1	20050217	AU 2004-262487	20040729
CA 2534136	A1	20050217	CA 2004-2534136	20040729
EP 1648444	A1	20060426	EP 2004-741320	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1832739	A	20060913	CN 2004-80022353	20040729
BR 2004013001	A	20060926	BR 2004-13001	20040729
JP 2007500167	T	20070111	JP 2006-521531	20040729
NO 2006000506	A	20060131	NO 2006-506	20060131
PRIORITY APPLN. INFO.:				
			ES 2003-1808	A 20030730
			WO 2004-EP8513	W 20040729

OTHER SOURCE(S): CASREACT 142:219149; MARPAT 142:219149
 GI



AB Title compds. I [R1 = NR8R9 radical or a (un)saturated, optionally at least monosubstituted cycloaliph. radical which may contain at least one heteroatom; R2-6 independently = H, halo, NO2, alkoxy, etc.; R7 = H or (un)saturated aliphatic radical optionally at least monosubstituted; R8 and R9

= H or (un)saturated aliphatic radical optionally at least monosubstituted with provisions, or R8 and R9 together with the N atom form a (un)saturated heterocyclic ring optionally at least monosubstituted; A = mono or polycyclic aromatic ring system which may be bonded via (un)substituted alkylene, alkenylene or alkynylene group; n = 0-4], and their pharmaceutically acceptable salts, are prepared and disclosed as useful for medicaments in human and/or veterinary therapeutics for diseases/disorders related to 5-HT6 receptor. Thus, e.g., II was prepared by the reaction of naphthalene-1-sulfonyl chloride with 7-amino-3-(2-dimethylaminoethyl)-1H-indole. I are disclosed as modulators for the 5HT6-receptor (no data).


IT 844486-21-1P 844486-22-2P 844486-23-3P
844486-24-4P 844486-25-5P 844486-26-6P
844486-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indol-7-ylsulfonamide derivs. as 5-HT6 receptor modulators)


RN 844486-21-1 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]-
(9CI) (CA INDEX NAME)




RN 844486-22-2 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 844486-23-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-24-4 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(dimethylamino)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-25-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




RN 844486-26-6 CAPLUS

CN 1-Naphthalenesulfonamide, N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]-
(9CI) (CA INDEX NAME)



RN 844486-27-7 CAPLUS

CN Imidazo[2,1-b]thiazole-5-sulfonamide, 6-chloro-N-[1-[2-(1-pyrrolidinyl)ethyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:389755 CAPLUS

DOCUMENT NUMBER: 139:270249

TITLE: New Analogues of the Anticancer E7070: Synthesis and
Pharmacology

AUTHOR(S): Laconde, G.; Pommery, N.; Depreux, P.; Berthelot, P.;
Henichart, J.-P.

CORPORATE SOURCE: Institut de Chimie Pharmaceutique Albert Lespagnol, EA
2692, Lille, 59006, Fr.

SOURCE: Journal of Enzyme Inhibition and Medicinal Chemistry
(2003), 18(2), 89-94
CODEN: JEIMAZ; ISSN: 1475-6366
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:270249


AB Cell cycle control in the G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins involved in G1 progression or G1/S transition have been found to play a crucial role in proliferation, differentiation, transformation, and programmed cell death (apoptosis). E7070 is a novel antitumor sulfonamide, with a unique mode of action that affects G1 progression of the cell cycle. A series of compds. containing an N-[1-(3,4,5-trimethoxybenzyl)-1H-indol-5-yl]benzene sulfonamide, analogs of E7070, was synthesized and evaluated as potential antitumor agents. Cell cycle anal. with PC3 human prostate cancer cells revealed a cellular accumulation in the G1 phase.

IT 605657-94-1P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and activity of anticancer E7070 analogs)

RN 605657-94-1 CAPLUS

CN Benzoic acid, 2-[[[1-[(3,4,5-trimethoxyphenyl)methyl]-1H-indol-7-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:29:39 ON 05 JUL 2007)

FILE 'REGISTRY' ENTERED AT 11:29:56 ON 05 JUL 2007

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 9 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:30:26 ON 05 JUL 2007

L4 5 S L3 FULL

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
27.29	199.60

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.90	-3.90

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:31:38 ON 05 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 29, 2007 (20070629/UP).

=> d his

(FILE 'HOME' ENTERED AT 11:29:39 ON 05 JUL 2007)

FILE 'REGISTRY' ENTERED AT 11:29:56 ON 05 JUL 2007

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 9 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:30:26 ON 05 JUL 2007

L4 5 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 11:31:38 ON 05 JUL 2007

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.36

199.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.90

STN INTERNATIONAL LOGOFF AT 11:35:21 ON 05 JUL 2007